DR. SHIVANI SHASHI KAMAT M.D.
Prescription History 1326368549
Ophthalmology - Glaucoma Specialist in Dallas, TX


Quality Rating: 74.59 out of 100 score

NPI Status: Active since June 10, 2010

Contact Information

5303 HARRY HINES BLVD
DALLAS, TX
ZIP 75390
Phone: (214) 645-2020

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. SHIVANI SHASHI KAMAT M.D., an active Glaucoma Specialist specialist practicing in Dallas, TX. Our medical registry currently tracks 26 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 5,250 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 1,846 claims alone.


Acetazolamide Er

Generic Formulation: AcetazolamideSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 21
30-Day Fills 41.0
Days Supply 1,230
TX State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills34.6
Peer Average Days Supply797
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,498.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$119.00

State Avg Cost Per Claim

$81.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)

Therapeutic Applications

Acetazolamide is used to prevent and reduce the symptoms of altitude sickness. This medication can decrease headache, tiredness, nausea, dizziness, and shortness of breath that can occur when you climb quickly to high altitudes (generally above 10,000 feet/3,048 meters). It is particularly useful in situations when you cannot make a slow ascent. The best ways to prevent altitude sickness are climbing slowly, stopping for 24 hours during the climb to allow the body to adjust to the new height, and taking it easy the first 1 to 2 days. This medication is also used with other medications to treat high pressure inside the eye due to certain types of glaucoma. Acetazolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. It works by decreasing the production of fluid inside the eye. It is also used to decrease a buildup of body fluids (edema) caused by heart failure or certain medications. Acetazolamide can work less well over time, so it is usually used only for a short period. It has also been used with other medications to treat certain types of seizures (petit mal and unlocalized seizures).

Alphagan P

Generic Formulation: Brimonidine TartrateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 208
30-Day Fills 326.0
Days Supply 9,262
TX State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills59.5
Peer Average Days Supply1,688
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 477.8% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $72,567.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$348.88

State Avg Cost Per Claim

$381.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Atropine Sulfate

Generic Formulation: Atropine SulfateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 16
30-Day Fills 23.7
Days Supply 664
TX State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills36.4
Peer Average Days Supply936
Conservative Utilization

This provider writes prescriptions for this formulation 38.5% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $833.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$52.09

State Avg Cost Per Claim

$50.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An alkaloid, originally from Atropa belladonna, but found in other plants, mainly SOLANACEAE. Hyoscyamine is the 3(S)-endo isomer of atropine.

Therapeutic Applications

This medication is used before eye examinations (such as refraction) and to treat certain eye conditions (such as uveitis). It belongs to a class of drugs known as anticholinergics. Atropine works by widening (dilating) the pupil of the eye.

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 420
30-Day Fills 852.0
Days Supply 24,926
TX State Average Benchmarks
Peer Average Claims72.0
Peer Average 30-Day Fills133.0
Peer Average Days Supply3,845
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 483.3% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,814.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$47.18

State Avg Cost Per Claim

$46.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Brimonidine Tartrate-Timolol

Generic Formulation: Brimonidine Tartrate/TimololSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 40
30-Day Fills 78.7
Days Supply 2,282
TX State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills49.9
Peer Average Days Supply1,423
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 33.3% more claims than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,134.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$278.35

State Avg Cost Per Claim

$307.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.

Therapeutic Applications

This combination medication is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This product contains brimonidine and timolol. These medications are used together when 1 drug is not controlling the pressure inside the eye. Brimonidine works by allowing better fluid drainage from within the eye and also by decreasing the amount of fluid formed in the eye. It belongs to a class of drugs known as alpha agonists. Timolol is thought to work by decreasing the amount of fluid formed in the eye. Timolol belongs to a class of drugs known as beta blockers. This medication is not recommended for use in children less than 2 years old due to an increased risk of serious side effects. Ask the doctor or pharmacist for more details.

Brinzolamide

Generic Formulation: BrinzolamideSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 26
30-Day Fills 59.7
Days Supply 1,790
TX State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills58.2
Peer Average Days Supply1,733
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,996.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$307.58

State Avg Cost Per Claim

$347.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Brinzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Combigan

Generic Formulation: Brimonidine Tartrate/TimololSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 87
30-Day Fills 165.9
Days Supply 4,871
TX State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills83.4
Peer Average Days Supply2,382
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 74.0% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $40,302.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$463.25

State Avg Cost Per Claim

$396.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.

Therapeutic Applications

This combination medication is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This product contains brimonidine and timolol. These medications are used together when 1 drug is not controlling the pressure inside the eye. Brimonidine works by allowing better fluid drainage from within the eye and also by decreasing the amount of fluid formed in the eye. It belongs to a class of drugs known as alpha agonists. Timolol is thought to work by decreasing the amount of fluid formed in the eye. Timolol belongs to a class of drugs known as beta blockers. This medication is not recommended for use in children less than 2 years old due to an increased risk of serious side effects. Ask the doctor or pharmacist for more details.

Cosopt Pf

Generic Formulation: Dorzolamide/Timolol/PfSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 16
30-Day Fills 24.0
Days Supply 720
TX State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply721
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,513.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$282.11

State Avg Cost Per Claim

$260.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 153
30-Day Fills 318.7
Days Supply 9,543
TX State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills111.2
Peer Average Days Supply3,318
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 178.2% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,515.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.51

State Avg Cost Per Claim

$32.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 926
30-Day Fills 2,094.1
Days Supply 62,661
TX State Average Benchmarks
Peer Average Claims98.0
Peer Average 30-Day Fills206.9
Peer Average Days Supply6,186
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 844.9% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $28,497.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.77

State Avg Cost Per Claim

$34.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide/Timolol/PfSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 34
30-Day Fills 56.5
Days Supply 1,695
TX State Average Benchmarks
Peer Average Claims98.0
Peer Average 30-Day Fills206.9
Peer Average Days Supply6,186
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.3% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,782.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$199.49

State Avg Cost Per Claim

$34.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Ketorolac Tromethamine

Generic Formulation: Ketorolac TromethamineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 42
30-Day Fills 45.3
Days Supply 1,015
TX State Average Benchmarks
Peer Average Claims84.0
Peer Average 30-Day Fills100.2
Peer Average Days Supply2,467
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,249.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.76

State Avg Cost Per Claim

$28.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.

Therapeutic Applications

This medication is used to temporarily relieve itching eyes caused by seasonal allergies. It is also used to prevent and treat eye swelling due to a certain type of eye surgery (cataract removal). Ketorolac belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It works by blocking certain natural substances in your body to reduce pain and swelling.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 1,846
30-Day Fills 3,461.3
Days Supply 99,261
TX State Average Benchmarks
Peer Average Claims161.0
Peer Average 30-Day Fills298.3
Peer Average Days Supply8,546
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 1,046.6% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $34,961.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.94

State Avg Cost Per Claim

$25.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 210
30-Day Fills 385.9
Days Supply 11,102
TX State Average Benchmarks
Peer Average Claims71.0
Peer Average 30-Day Fills126.0
Peer Average Days Supply3,626
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 195.8% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $106,760.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$508.38

State Avg Cost Per Claim

$471.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Methazolamide

Generic Formulation: MethazolamideSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 133
30-Day Fills 170.1
Days Supply 4,898
TX State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills35.2
Peer Average Days Supply1,011
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 504.5% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,519.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$229.47

State Avg Cost Per Claim

$385.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to certain types of glaucoma. Lowering high pressure inside the eye helps to prevent blindness, vision loss, and nerve damage. Methazolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. It works by decreasing the production of fluid inside the eye.

Moxifloxacin

Generic Formulation: Moxifloxacin HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 66
30-Day Fills 66.8
Days Supply 1,045
TX State Average Benchmarks
Peer Average Claims101.0
Peer Average 30-Day Fills102.9
Peer Average Days Supply1,617
Conservative Utilization

This provider writes prescriptions for this formulation 34.7% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,345.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.54

State Avg Cost Per Claim

$36.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.

Therapeutic Applications

This medication is a quinolone antibiotic used for eye infections.

Pilocarpine Hcl

Generic Formulation: Pilocarpine HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 48
30-Day Fills 119.3
Days Supply 3,502
TX State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills49.9
Peer Average Days Supply1,475
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 84.6% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,396.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$91.59

State Avg Cost Per Claim

$90.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.

Therapeutic Applications

This medication is used to treat symptoms of dry mouth due to a certain immune disease (Sjogren's syndrome) or from saliva gland damage due to radiation treatments of the head/neck for cancer. Pilocarpine belongs to a class of drugs known as cholinergic agonists. It works by stimulating certain nerves to increase the amount of saliva you produce, making it easier and more comfortable to speak and swallow.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 177
30-Day Fills 244.6
Days Supply 6,453
TX State Average Benchmarks
Peer Average Claims130.0
Peer Average 30-Day Fills168.2
Peer Average Days Supply4,409
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 36.2% more claims than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,562.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$48.38

State Avg Cost Per Claim

$51.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Rhopressa

Generic Formulation: Netarsudil MesylateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 95
30-Day Fills 158.2
Days Supply 4,500
TX State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills83.0
Peer Average Days Supply2,321
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 75.9% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $47,138.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$496.19

State Avg Cost Per Claim

$469.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Netarsudil is used to treat high pressure inside the eye due to certain eye conditions (such as open-angle glaucoma, ocular hypertension). This medication is thought to work by increasing the flow of fluid out of the eye. This helps lower pressure inside the eye. Lowering high pressure inside the eye can help prevent loss of vision or blindness.

Rocklatan

Generic Formulation: Netarsudil Mesylat/LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 20
30-Day Fills 33.6
Days Supply 973
TX State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills59.1
Peer Average Days Supply1,604
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.2% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,693.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$534.67

State Avg Cost Per Claim

$488.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Netarsudil/latanoprost is used to treat high pressure inside the eye due to certain eye conditions (such as open-angle glaucoma, ocular hypertension). Lowering high pressure inside the eye can help prevent vision loss or blindness.

Simbrinza

Generic Formulation: Brinzolamide/Brimonidine TartSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 32
30-Day Fills 55.0
Days Supply 1,650
TX State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills42.7
Peer Average Days Supply1,233
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,388.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$324.63

State Avg Cost Per Claim

$256.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two medications used to treat high pressure in the eye due to glaucoma (open-angle glaucoma-type) or a certain other eye disease (ocular hypertension). Lowering high pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This product contains brinzolamide and brimonidine. These two medications work together to decrease the amount of fluid within the eye. Brinzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. Brimonidine belongs to a class of drugs known as alpha agonists. This product is not recommended for use in children younger than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 411
30-Day Fills 991.3
Days Supply 29,447
TX State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills26.0
Peer Average Days Supply774
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 2,640.0% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,915.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.96

State Avg Cost Per Claim

$484.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Travoprost

Generic Formulation: TravoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 128
30-Day Fills 218.6
Days Supply 6,225
TX State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills68.2
Peer Average Days Supply1,962
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 228.2% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $26,952.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$210.56

State Avg Cost Per Claim

$245.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Vyzulta

Generic Formulation: Latanoprostene BunodSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 48
30-Day Fills 83.8
Days Supply 2,403
TX State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills61.0
Peer Average Days Supply1,715
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $25,930.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$540.22

State Avg Cost Per Claim

$420.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Latanoprostene bunod is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by controlling the flow of fluid within the eye to maintain a normal pressure.

Xalatan

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 22
30-Day Fills 23.4
Days Supply 596
TX State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills19.9
Peer Average Days Supply520
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.1% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,026.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$273.93

State Avg Cost Per Claim

$361.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Zioptan

Generic Formulation: Tafluprost/PfSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 25
30-Day Fills 33.0
Days Supply 900
TX State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills37.2
Peer Average Days Supply1,099
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,413.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$296.56

State Avg Cost Per Claim

$370.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tafluprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. SHIVANI SHASHI KAMAT M.D. provides transparency into local medical care patterns within Dallas, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Glaucoma Specialist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.